m+Medelevator.RU
← Поиск публикаций
Rare tumors · 2026

T-cell lymphoma of the breast and ovary presenting as a second malignant neoplasm in a pediatric leukemia survivor: A case report and literature review.

Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Alvarez-Palacios Oscar, Ojeda-Campos Luis, Rodríguez Alfredo, Díaz-Juarez Gabriel Ernesto, Figueroa-Torres José Manuel, Juárez-Velázquez Rocío, Juárez-Figueroa Ulises, Gallardo-Navarro Jorge Johans, Segundo-Galvez Luis Fabian, Ocampo-Bárcenas Azucena

Аннотация

Second malignant neoplasms (SMNs) are rare but serious late effects in childhood acute lymphoblastic leukemia (ALL) survivors. Mature peripheral T-cell lymphomas involving both the breast and ovary are exceedingly rare, and their relationship with germline predisposition variants remains poorly understood. We report a 17-year-old female, previously treated for high-risk B-cell ALL and in sustained remission, who developed bilateral breast and ovarian masses in 2024. Histopathology and immunohistochemistry confirmed a mature T-cell lymphoma (CD7+, CD99+, weak CD5/CD3, Ki-67 >90%, TdT-). Whole-exome sequencing revealed a germline pathogenic BRCA2 variant (c.1910-2A>T) along with additional likely pathogenic variants (CUX1, MED12L, POLR3B, PIK3CA). The disease progressed rapidly despite CHOP chemotherapy, and the patient died shortly after diagnosis. This report describes an exceptionally rare SMN of peripheral T-cell lymphoma with breast and ovarian involvement in a pediatric leukemia survivor. The coexistence of a germline BRCA2 mutation and additional genomic alterations suggests a multigenic predisposition hypothesis. Early incorporation of next-generation sequencing may uncover molecular vulnerabilities and inform alternative therapeutic strategies in refractory hematologic malignancies.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты